Amgen Inc. (AMGN) 10-K Red Flags
Risk signals extracted deterministically from Amgen Inc.’s SEC 10-K/10-Q XBRL filings — no LLM, every finding cites the underlying data.
Detected red flags (14)
- Receivables outpacing revenue: Accounts receivable grew +41.1% YoY vs revenue growth of +10.0%. The +31.2% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
- Earnings-cash flow divergence: Net income grew +88.5% while operating cash flow declined -13.3%. This divergence may indicate accrual-based earnings inflation — non-cash gains, aggressive revenue recognition, or working capital absorption. The accrual ratio (NI − OCF) is deteriorating.
- Free cash flow deteriorating: FCF declined +22.1% YoY (from $10.39B to $8.10B). With OCF at $9.96B and capex at $1.86B, cash generation capacity is weakening — monitor for dividend/buyback sustainability.
- Operating cash flow exceeds net income: OCF is 1.29x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- NEW: Off-balance sheet arrangements: Off-balance sheet arrangements appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: Revenue grew +10.0% but receivables grew +41.1% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
- Endogenous analysis: Free cash flow declined despite stable or rising capex, indicating the cash burn is operational rather than investment-driven. This is a structural concern — cost reduction or asset sales may be needed to restore FCF.
- 3 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 1 new risk-language term(s) detected in filing text: Off-balance sheet arrangements.
- Market cap $229.92B at $425.28 per share.
- Trailing P/E 29.89, P/S 6.26, P/B 19.67.
- Receivables outpacing revenue: Accounts receivable grew +41.1% YoY vs revenue growth of +10.0%. The +31.2% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
- Earnings-cash flow divergence: Net income grew +88.5% while operating cash flow declined -13.3%. This divergence may indicate accrual-based earnings inflation — non-cash gains, aggressive revenue recognition, or working capital absorption. The accrual ratio (NI − OCF) is deteriorating.
Filings & ownership
- Latest annual report (10-K) filed Feb 13, 2026.
- Latest quarterly report (10-Q) filed Aug 5, 2026.
- 9 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 4 sell transactions — net selling $2.9M.
- ~10,000+ recent 13F-HR filings reference Amgen Inc.; broad institutional reporting.
- Recent filers include THURSTON, SPRINGER, MILLER, HERD & TITAK, INC., Visium Asset Management LLC, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
- 12 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 8 recent 13G passive institutional ownership notices.
Full AMGN analyst report
Valuation (DCF & Graham), technicals, macro exposure, risk scorecard and 13F/13D ownership.
View full report →Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.